Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939366 | 0.92 | CYP1A2 (0.38) | MAP1LC3BMAP1LC3A | |
| SCHEMBL11934013 | 0.89 | HIF1A (0.40) | MEN1KMT2AMAP1LC3BMAP1LC3A | |
| SCHEMBL11933978 | 0.89 | PTPRC (0.42) | MEN1KMT2AMAP1LC3BMAP1LC3A | |
| SCHEMBL11933985 | 0.89 | EGLN1 (0.39) | EGLN1EGLN3MEN1KMT2AMAP1LC3B | |
| SCHEMBL11939629 | 0.89 | HIF1A (0.42) | EGLN1ESR1 | |
| SCHEMBL11933982 | 0.88 | HIF1A (0.41) | EGLN1EGLN3ESR1MEN1KMT2A | |
| SCHEMBL11933995 | 0.87 | MAP1LC3B (0.37) | MEN1KMT2AMAP1LC3BMAP1LC3A | |
| SCHEMBL11933990 | 0.87 | MAP1LC3B (0.37) | MAP1LC3BMAP1LC3A | |
| SCHEMBL11933989 | 0.87 | HIF1A (0.42) | MAP1LC3BMAP1LC3A | |
| SCHEMBL11933987 | 0.87 | MAPK1 (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | HIF1AN, HIF1A, EGLN3 | EGLN2 4/4885EGLN1 5/4885EGLN3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.